This website uses cookies to understand how you use the website and to improve your experience. By continuing to use the website, you accept the University of New England’s use of cookies and similar technologies. To learn more about our use of cookies and how to manage your browser cookie settings, please review our Privacy Notice.


Deleterious Effects of Sustained Morphine on Bone Cancer Pain and Disease Progression

Seminar Center for Excellence in the Neurosciences Seminar Series

Anna Vardanyan, M.D., Ph.D.

Staff Scientist II, Department of Orthopaedic Research, Genzyme Corporation, Framingham, MA


Dr. Anna Vardanyan received her M.D. in 2001 from Yerevan State Medical University in Armenia. She went on to earn a Ph.D. in Medical Pharmacology from the University of Arizona College of Medicine in 2007. After completing the PhD program, she was recruited to Genzyme Corporation in 2008, to establish a pain program within the Department of Orthopaedic Research, where she currently holds the position of Staff Scientist II.

Her efforts are focused on setting strategy and leading Osteoarthritis Pain Project. This includes target identification, discovery research and preclinical assessment of novel therapeutic candidates for the treatment of OA pain.

Dr. Vardanyan’s research interests include opioid-induced adaptive changes in pain processing, as well as the neurobiology and pharmacologic management of bone cancer-induced and osteoarthritis-induced pain.


Center for Excellence in Neurosciences


12:00 PM
Bush Center Conference Room

Biddeford Campus

Free and open to the public